Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - NETs and endocrine tumours

1162MO - Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results


18 Sep 2020


Mini Oral - NETs and endocrine tumours


Marianne Pavel


Annals of Oncology (2020) 31 (suppl_4): S711-S724. 10.1016/annonc/annonc281


M.E. Pavel1, J. Ćwikła2, C. Lombard-Bohas3, I. Borbath4, T. Shah5, U. Pape6, X. Truong Thanh7, A. Houchard8, P. Ruszniewski9

Author affiliations

  • 1 Department Of Medicine, Friedrich Alexander University Erlangen-Nürnberg, 91054 - Erlangen/DE
  • 2 ., University of Warmia and Mazury, Olsztyn/PL
  • 3 Hcl Cancer Institute, Edouard-Herriot Hospital, Lyon/FR
  • 4 ., Cliniques Universitaires St. Luc - Université Catholique de Louvain, 1200 - Brussels/BE
  • 5 ., Queen Elizabeth Hospital Birmingham, Birmingham/GB
  • 6 Asklepios Medical School, Asklepios Klinik St. Georg, Hamburg/DE
  • 7 Medical Affairs, Ipsen, 92100 - Boulogne-Billancourt/FR
  • 8 Statistics, Ipsen, Boulogne-Billancourt/FR
  • 9 University Of Paris, Beaujon Hospital, 92110 - Clichy/FR


Login to access the resources on OncologyPRO.

Abstract 1162MO


CLARINET FORTE assessed the efficacy and safety of increasing LAN 120 mg dose frequency from every (q) 28 days (standard) to q14 days in patients with a progressive pancreatic NET (panNET) or midgut NET.


A prospective, single-arm, open-label, exploratory, international phase II study in patients with a metastatic or locally advanced, unresectable, G1/2 panNET or midgut NET, with centrally assessed progression within the last 2 years while on a standard LAN regimen for ≥24 weeks. Planned recruitment was 50 patients per cohort. LAN 120 mg q14 days was administered for 48 (panNET) or 96 (midgut) weeks (or until centrally-assessed progressive disease, unacceptable toxicity/tolerability, or death), or longer if <25 events had occurred.


In the panNET (N=48) and midgut NET (N=51) cohorts, respectively, median (95% confidence interval [CI]) progression-free survival (PFS, primary endpoint) was 5.6 (5.5; 8.3) and 8.3 (5.6; 11.1) months. Post-hoc subgroup analysis in the panNET cohort showed median (95% CI) PFS of 8.0 (5.6; 8.3) months in patients with Ki67 ≤10% (N=43), and 2.8 (2.8; 2.9) months in patients with Ki67 >10% (N=5). Disease control rate (DCR; proportion of patients with complete response, partial response or stable disease; 95% CI) in the panNET and midgut NET cohorts, respectively: Week 24, 43.8% (29.5; 58.8) and 58.8% (44.2; 72.4); Week 48, 22.9% (12.0; 37.3) and 33.3% (20.8; 47.9). Treatment-related adverse events (TRAEs) occurred in 37.5% and 51.0% of patients in the panNET and midgut NET cohorts, respectively; only one TRAE was G≥3 (panNET: fatigue [N=1], G3). The most common (≥10%) classes of TRAEs were gastrointestinal disorders (panNET, 25.0%; midgut NET, 37.3%) and general disorders/administration-site conditions (midgut NET, 13.7%). Of note, the following TRAEs occurred: hyperglycaemia (N=2), bile stones (N=1), steatorrhea (N=1).


LAN 120 mg q14 days in patients with panNETs or midgut NETs (progressive on standard LAN dose) produced promising PFS and DCR. In the pan-NET cohort, the outcome was more favourable in patients with Ki67 ≤10%. Safety was consistent with the known safety profile of LAN.

Clinical trial identification


Editorial acknowledgement

Jessica Woods, BMedSci (Hons), on behalf of Watermeadow Medical, an Ashfield company, provided medical writing support, which was funded by the study sponsor in accordance with Good Publication Practice guidelines.

Legal entity responsible for the study





M.E. Pavel: Honoraria (self), Advisory/Consultancy: Ipsen; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Pfizer; Honoraria (self), Advisory/Consultancy: AAA; Honoraria (self), Advisory/Consultancy: Lexicon. J.B. Ćwikła: Honoraria (self): Ipsen. C. Lombard-Bohas: Advisory/Consultancy, Research grant/Funding (self): Ipsen; Advisory/Consultancy: Pfizer; Advisory/Consultancy, Research grant/Funding (self): Novartis. I. Borbath: Advisory/Consultancy: Pfizer; Advisory/Consultancy, Research grant/Funding (self): Novartis; Advisory/Consultancy, Research grant/Funding (self): Ipsen; Research grant/Funding (self): Bayer; Research grant/Funding (self): Celgene. T. Shah: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen. U-F. Pape: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self): Ipsen; Honoraria (self), Research grant/Funding (self): Novartis. X-M. Truong Thanh: Full/Part-time employment: Ipsen. A. Houchard: Full/Part-time employment: Ipsen. P. Ruszniewski: Advisory/Consultancy: Novartis; Advisory/Consultancy: Ipsen; Advisory/Consultancy: AAA; Advisory/Consultancy: ITM; Advisory/Consultancy: Keocyt.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings